Brokers Issue Forecasts for ESPR FY2027 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Zacks Research issued their FY2027 EPS estimates for Esperion Therapeutics in a note issued to investors on Tuesday, March 25th. Zacks Research analyst K. Das anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the year. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price for the company. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday, March 20th. Finally, JMP Securities reiterated a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, Esperion Therapeutics has an average rating of “Hold” and an average price target of $6.75.

Esperion Therapeutics Trading Down 1.2 %

Shares of ESPR opened at $1.61 on Thursday. Esperion Therapeutics has a 12 month low of $1.47 and a 12 month high of $3.94. The stock has a fifty day moving average price of $1.79 and a 200-day moving average price of $2.07. The firm has a market cap of $318.54 million, a PE ratio of -2.52 and a beta of 1.04.

Institutional Trading of Esperion Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Summit Financial LLC boosted its holdings in Esperion Therapeutics by 18.2% in the fourth quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 7,150 shares during the last quarter. Foundations Investment Advisors LLC lifted its holdings in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 9,872 shares during the period. Invesco Ltd. boosted its stake in shares of Esperion Therapeutics by 15.5% in the fourth quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 13,101 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Esperion Therapeutics by 0.4% during the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after acquiring an additional 16,100 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in Esperion Therapeutics by 15.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 123,896 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 16,404 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.